Despite the systematically analysis of SLC35A2 in this study, there still exist the following shortcomings: Firstly, in vivo and in vitro validation should be carried out to determine the clinical validity of SLC35A2 in patient prognosis and the mechanism of promoting tumor. Here, SLC35A2 is linked to neoplasm.